Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Sleep duration implicated in cognition

12 Jun 2019

Both short and long sleep duration are associated with poorer cognitive outcomes, exerting a small negative effect on reaction time and visual memory, as reported in a recent study.

Researchers conducted a Mendelian randomization (MR) study with 77 single-nucleotide polymorphisms (SNPs) for sleep duration. They collected individual-participant data from the UK Biobank cohort (n=395,803; mean age, 56.9 years; 54 percent female) and summary statistics from the International Genomics of Alzheimer’s Project (cases: n=17,008; controls: n=37,154) to examine the potential impact of sleep duration on cognitive outcomes.

The average sleep duration in the cohort was 7.17 hours/day. There were U-shaped/inverted U-shaped patterns across sleep duration categories for most variables. Compared with those who reported sleeping for 7 hours/day, participants in both <7 and >7 hours/day sleep categories had lower scores in the baseline visual-memory and reaction-time tests.

The worst scores were observed among participants sleeping 10–12 hours/day (average number of incorrect matches in visual-memory test, 4.6; average reaction time, 591 milliseconds). Linear MR indicated that each additional hour/day of sleep slowed reaction time by 1 percent (p=0.008) and increased errors in visual-memory test by 3 percent (p=0.05).

There was, however, little evidence to support associations between increased sleep duration and visual memory decline (odds ratio [OR] per additional hour/day of sleep, 1.10, 95 percent CI, 0.76–1.57; p=0.62), reaction time decline (OR, 1.28, 0.49–3.35; p=0.61), all-cause dementia (OR, 1.19, 0.65–2.19; p=0.57) or Alzheimer’s disease risk (OR, 0.89, 0.67–1.18; p=0.41).

Meanwhile, nonlinear MR showed both short and long sleep duration to be associated with poorer visual memory (p-nonlinearity=3.44–9) and reaction time (p-nonlinearity=6.66–16).

The findings suggest that increased sleep duration may be causally related to poorer reaction time and visual memory, despite relatively small linear-effect sizes, the researchers said.

Therefore, improved sleep habits could represent a potential therapeutic target for cognition, which is important as there is currently no single-measure treatment that can decelerate cognitive decline or the risk of dementia, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.